CRIS Current Research Information System

LANZA, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.993
EU - Europa 1.626
AS - Asia 1.596
SA - Sud America 135
AF - Africa 69
OC - Oceania 4
Totale 5.423
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.966
CN - Cina 654
IT - Italia 616
SG - Singapore 569
GB - Regno Unito 199
DE - Germania 186
VN - Vietnam 160
SE - Svezia 121
BR - Brasile 118
NL - Olanda 105
IE - Irlanda 71
RU - Federazione Russa 70
IN - India 56
HK - Hong Kong 49
UA - Ucraina 44
FR - Francia 43
CH - Svizzera 38
FI - Finlandia 35
BG - Bulgaria 33
KR - Corea 26
ID - Indonesia 22
CA - Canada 21
CI - Costa d'Avorio 21
TG - Togo 17
EE - Estonia 15
ZA - Sudafrica 15
JO - Giordania 14
AT - Austria 12
TR - Turchia 11
JP - Giappone 10
NG - Nigeria 10
BE - Belgio 7
ES - Italia 6
AR - Argentina 5
GR - Grecia 5
MX - Messico 5
IQ - Iraq 4
PL - Polonia 4
AU - Australia 3
CL - Cile 3
KE - Kenya 3
LT - Lituania 3
MY - Malesia 3
PY - Paraguay 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BO - Bolivia 2
DK - Danimarca 2
HR - Croazia 2
IS - Islanda 2
MA - Marocco 2
OM - Oman 2
PK - Pakistan 2
PS - Palestinian Territory 2
RO - Romania 2
UZ - Uzbekistan 2
BY - Bielorussia 1
CZ - Repubblica Ceca 1
EG - Egitto 1
GE - Georgia 1
HU - Ungheria 1
IR - Iran 1
KZ - Kazakistan 1
LB - Libano 1
LI - Liechtenstein 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PA - Panama 1
PE - Perù 1
PH - Filippine 1
PT - Portogallo 1
Totale 5.423
Salva come PNG Salva come JPEG
Città #
Singapore 431
Boardman 271
Santa Clara 241
Fairfield 170
Southend 166
Ashburn 128
Chandler 105
Bologna 83
Woodbridge 77
Dublin 71
Houston 71
Wilmington 67
Seattle 65
Ann Arbor 61
Cambridge 51
Milan 51
Hong Kong 48
Princeton 46
Frankfurt am Main 44
Dong Ket 39
Los Angeles 36
Sofia 33
Shanghai 32
Guangzhou 29
Beijing 28
Bern 28
Florence 26
Helsinki 26
New York 25
Jacksonville 24
Padova 24
Seoul 23
Abidjan 21
Rome 21
Turin 21
Jakarta 20
Nanjing 19
Zhengzhou 19
Lomé 17
Nuremberg 17
Westminster 17
Amman 14
Naples 13
Changsha 12
Xi'an 12
Arezzo 11
Genoa 11
Jinan 11
Munich 11
Shenyang 11
Shijiazhuang 11
Tianjin 11
Berlin 10
Falkenstein 10
Forlì 10
Fort Worth 10
Redmond 10
Saint Petersburg 10
São Paulo 9
Toronto 9
Abeokuta 8
Bremen 8
Cesena 8
Mülheim 8
Suzhou 8
Wuhan 8
Brussels 7
Dongguan 7
Hangzhou 7
Hebei 7
Jiaxing 7
Lappeenranta 7
Lugo 7
Nanchang 7
Prineville 7
Qingdao 7
Taiyuan 7
Belvedere Spinello 6
Catanzaro 6
Chengdu 6
Chicago 6
Foshan 6
Medford 6
Modena 6
Pisa 6
San Diego 6
Wenzhou 6
Yubileyny 6
Hefei 5
Istanbul 5
Izumo 5
Kunming 5
Monza 5
Mumbai 5
Rio de Janeiro 5
Springfield 5
Uppsala 5
Vienna 5
Amsterdam 4
Cagliari 4
Totale 3.247
Salva come PNG Salva come JPEG
Nome #
Stem Cells 266
A simple method for identifying bone marrow mesenchymal stromal cells with a high immunosuppressive potential. 195
A decreased positivity for CD90 on human mesenchymal stromal cells (MSCs) is associated with a loss of immunosuppressive activity by MSCs. 184
Isolation of stem cell populations with trophic and immunoregulatory functions from human intestinal tissues: potential for cell therapy in inflammatory bowel disease. 180
Cellule staminali. Embrionali, mesenchimali, emopoietiche, intestinali, cardiovascolari, muscolari, nervose e placentari 179
A functional role for soluble HLA-G antigens in immune modulation mediated by mesenchymal stromal cells. 143
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 139
Umbilical cord blood CD34(+)cell-derived progeny produces human leukocyte antigen-G molecules with immuno-modulatory functions. 130
Azacitidine low-dose schedule in low-risk myelodysplastic syndromes. Clinical results of a multicenter phase II study 124
Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia. 112
European Data on Stem Cell Mobilization with Plerixafor in Non-Hodgkin’s Lymphoma, Hodgkin’s Lymphoma and Multiple Myeloma Patients. A Subgroup Analysis of the European Consortium of Stem Cell Mobilization. 112
null 97
Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF. 87
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia 85
Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo italianoTrapianto di Midollo Osseo. 83
null 81
Vinciamo la vita. Oltre la cura il benessere. Un percorso di lungo periodo nell'alleanza medico paziente-famiglia. 80
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. 80
null 77
null 76
Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia 67
Pharmacological inhibition of wip1 sensitizes acute myeloid leukemia cells to the mdm2 inhibitor nutlin-3a 67
Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients 62
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 51
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 48
Ibrutinib: from bench side to clinical implications 40
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 39
CD22 expression in b-cell acute lymphoblastic leukemia: Biological significance and implications for inotuzumab therapy in adults 37
Novel insights and therapeutic approaches in secondary AML 37
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin 35
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a 34
Efficacy and Safety of Biosimilar Candidate ABP 959 As Compared with Eculizumab Reference Product in Paroxysmal Nocturnal Hemoglobinuria 34
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 34
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 34
Lenalidomide plus rituximab for the initial treatment of elderly frail patients with DLBCL: the FIL_ReRi Phase 2 Study 33
Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model 31
Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy 29
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV 29
Veno-Occlusive Disease Risk and Other Outcomes in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia Who Received Inotuzumab Ozogamicin and Proceeded to Hematopoietic Stem Cell Transplantation: A Registry-Based, Observational Study 29
Autologous stem cell transplantation (ASCT) for acute myeloid leukemia in patients in first complete remission after one versus two induction courses: A study from the ALWP of the EBMT 28
New Horizons in Immunology and Immunotherapy of Acute Leukemias and Related Disorders 28
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol 28
Expression of the immunoglobulin superfamily cell membrane adhesion molecule Cd146 in acute leukemia 26
CD123 (Interleukin 3 receptor a chain) 26
INO-CD22: A Multi-Center, Real-Life Study on Inotuzumab-Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia 25
A report from the SIdEM: Italy 25
Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients 24
Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study 24
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk breast cancer: results from the italian National Registry 23
Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study 23
Novel approaches for hematopoietic stem cell mobilisation and collection need to be assessed for qualification and validation to accomplish the proper requirements of their intended purpose 23
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi 23
Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study 23
Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis 23
Identification of Novel Potential Predisposing Variants in Familial Acute Myeloid Leukemia 22
Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation 22
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial 22
Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment 21
Alloreactivity: the Janus-face of hematopoietic stem cell transplantation 21
Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3 internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation 21
Long-Term Outcome of Peripheral Blood Autologous Stem Cell Transplantation (AutoSCT) for De Novo Acute Myeloid Leukemia in Patients Achieving First Complete Remission after One Vs Two Induction Courses: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) 21
Isolamento e caratterizzazione immunofenotipica di cellule non-emopoietiche presenti in versamenti ascitici e pleurici di pazienti con malattie ematologiche 20
Citometria a flusso: applicazioni in ematologia 20
Cellule staminali circolanti in pazienti con infarto miocardico 20
CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) 20
The Circular Life of Human CD38: From Basic Science to Clinics and Back 20
Results of the 6-Year Follow- up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia 20
CD116 (GM-CSF-R) 20
RISK-ADAPTED MRD-DIRECTED THERAPY FOR YOUNG ACUTE MYELOID LEUKEMIA ADULTS: 6-YEAR UPDATE OF THE GIMEMA AML1310 TRIAL 20
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 20
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency 19
Cytogenetic aspects of B- cell chronic lymphocytic leukemia: their correlation with clinical stage and different polyclonal mitogens 19
The Sorafenib plus Nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of the FLT3 and p53 status 19
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents 19
Benessere Condiviso 18
Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria 18
Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) 18
XXXI National Conference of the Italian Society of Cytometry (GIC) October 8–11, 2013, Lucca, Italy 18
Alpha interferon in T helper phenotype chronic lymphocytic leukemia: a report of three cases 18
Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders 18
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 18
A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach 18
Long-term survival can be achieved in a significant fraction of older patients with core binding factor acute myeloid leukemia treated with intensive chemotherapy 18
Cytogenetic and molecular cytogenetic profile of bone marrow-derived mesenchymal stromal cells in chronic and acute lymphoproliferative disorders 17
CXCR4 pos circulating progenitor cells coexpressing monocytic and endothelial markers correlating with fibrotic clinical features are present in the peripheral blood of patients affected by systemic sclerosis 17
Aberrant expression of HLA-DR antigen by bone marrow-derived mesenchymal stromal cells from patients affected by acute lymphoproliferative disorders 17
Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) 17
Basophil count in samples from chronic leukaemia patients analysed by the automated flow cytochemistry technology 17
The oldest case of lymphoma? Insights from a XIII century fresco 17
Development of adaptive immune effector therapies in solid tumors 16
Cellule staminali circolanti in pazienti con infarto miocardico 16
Targeted Therapies and Druggable Genetic Anomalies in Acute Myeloid Leukemia: From Diagnostic Tools to Therapeutic Interventions 16
Acute leukemia following a previous malignancy: do acute lymphoid leukemia and acute myeloid leukemia have a common risk factors ? 15
Thrombocytosis in systemic lupus erythematosus: a possible clue to autosplenectomy? 15
Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia 15
Eterogeneita' immunofenotipica di cellule staminali mesenchimali dopo espansione ex vivo 15
Hereditary myeloperoxidase deficiency syndrome. Clinical and hematological data of ten cases 15
Salvage High-Dose Chemotherapy for Relapsed Pure Seminoma in the Last 10 Years: Results From the European Society for Blood and Marrow Transplantation Series 2002-2012 15
5 Anni di Ematologia a Ravenna e in Romagna 15
In Memoriam of Riccardo Saccardi (Careggi University Hospital, Florence), eminent hematologist and a remarkable innovator in the treatment of autoimmune diseases by means of novel methodologies in HSC transplantation 15
Totale 4.490
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.993
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.993
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202060 0 0 0 0 0 0 0 0 0 0 25 35
2020/2021365 55 23 9 13 3 11 1 33 43 15 23 136
2021/2022500 79 3 31 29 40 30 18 35 14 50 99 72
2022/2023932 50 69 35 61 34 37 12 149 165 132 92 96
2023/2024650 35 61 66 58 75 93 36 50 34 64 38 40
2024/20252.650 91 272 318 208 591 144 403 95 121 326 81 0
Totale 5.853